Spero therapeutics to present at the evercore isi healthconx conference on december 3, 2020

Cambridge, mass., nov. 30, 2020 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that ankit mahadevia, m.d., president and chief executive officer of spero therapeutics, will participate in a fireside chat at the 3rd annual evercore isi healthconx conference taking place december 1 – 3, 2020.
SPRO Ratings Summary
SPRO Quant Ranking